The MSI-PCR platform established for the analysis of CRC here is also readily applicable for analyzing the MSI phenotypes in other types of cancer where the PD-1/PD-L1 immunotherapies are feasible [20, 25, 26]. This evidence concerns the gene PDCD1 and colorectal carcinoma.